Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0YR1V
|
||||
Former ID |
DNC004212
|
||||
Drug Name |
5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
Download2D MOL |
||||
Formula |
C16H16N6
|
||||
Canonical SMILES |
CCCCC1=NC2=NC=NC2=C3N1NC(=N3)C4=CC=CC=C4
|
||||
InChI |
1S/C16H16N6/c1-2-3-9-12-19-15-13(17-10-18-15)16-20-14(21-22(12)16)11-7-5-4-6-8-11/h4-8,10H,2-3,9H2,1H3,(H,20,21)
|
||||
InChIKey |
VAZLEKNDVCJXNR-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [1] | |
Adenosine A2a receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Rap1 signaling pathway | ||||
Calcium signaling pathway | |||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Vascular smooth muscle contraction | |||||
Parkinson's disease | |||||
Alcoholism | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
Reactome | Adenosine P1 receptors | ||||
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation | |||||
G alpha (s) signalling events | |||||
Surfactant metabolism | |||||
WikiPathways | Nucleotide GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCRs, OtherWP80:Nucleotide GPCRs | |||||
Monoamine Transport | |||||
NGF signalling via TRKA from the plasma membrane | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6.Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.